The American Cancer Society (ACS) estimates that in 2010:
Prostate cancer will account for about 1 in 4 newly diagnosed cancers each year among US men.
An estimated 217,730 new cases of prostate cancer will be diagnosed in the US
Approximately 32,050 men are expected to die from prostate cancer. Prostate cancer is the second most common cause of cancer death in men.
African American men have a higher incidence of prostate cancer and are more likely to die from the disease than white men in every age group.
In 2002-2006, the overall age adjusted incidence rate for white men was 146.3 per 100,000 and for African American men, it was 231.9 per 100,000. During the same time period, the mortality rate for white men was 23.6 per 100,000 and for African American men it was 56.3 per 100,000.
Prostate Cancer Treatment at Penn Today there is more hope than ever for those diagnosed with prostate cancer. Penn's Abramson Cancer Center has one of the nation's leading multi-displinary programs for the diagnosis and treatment of prostate.
Advanced Medicine... Innovative Research
Penn urologists are world renowned in cutting edge surgical techniques, such as nerve-sparing and robotically-assisted prostatectomy.
Penn urologists developed surgical treatment techniques to preserve urinary and sexual function
Penn performs more prostatectomies than any other Greater Philadelphia hospital.
Penn is a leader in interdisciplinary prostate cancer care, including the establishment of a team approach that includes designated urologists, as well as, radiation and medical oncologists.
U.S. News & World Report rank Penn's urology program the highest in the region.
Many of the physicians from Penn's Urologic Cancer Program are recognized repeatedly by Best Doctors in America and Philadelphia Magazine's Top Docs issue.
Penn was rewarded an $8.5 million grant to our Cancer Epidemiology and Risk Reduction Program from the National Cancer Institute to initiate studies to understand why African Americans have poorer outcomes when they are diagnosed with prostate cancer.